FY2026 Earnings Forecast for NRSN Issued By Noble Financial

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN) – Research analysts at Noble Financial issued their FY2026 earnings per share (EPS) estimates for NeuroSense Therapeutics in a research report issued on Thursday, June 25th. Noble Financial analyst R. Leboyer forecasts that the company will earn ($0.37) per share for the year. The consensus estimate for NeuroSense Therapeutics’ current full-year earnings is ($0.39) per share.

NRSN has been the subject of several other reports. D. Boral Capital restated a “buy” rating and set a $14.00 target price on shares of NeuroSense Therapeutics in a research report on Wednesday, April 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of NeuroSense Therapeutics in a research report on Friday, May 8th. Finally, Roth Mkm began coverage on NeuroSense Therapeutics in a report on Tuesday, March 10th. They set a “buy” rating and a $3.00 price objective for the company. One analyst has rated the stock with a Strong Buy rating, two have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Price Performance

NRSN opened at $0.76 on Monday. The company has a fifty day moving average price of $0.79 and a 200-day moving average price of $0.84. The firm has a market capitalization of $24.66 million, a P/E ratio of -1.40 and a beta of 1.56. NeuroSense Therapeutics has a one year low of $0.63 and a one year high of $2.19.

Institutional Investors Weigh In On NeuroSense Therapeutics

Several hedge funds have recently added to or reduced their stakes in NRSN. Two Sigma Investments LP purchased a new position in shares of NeuroSense Therapeutics in the 3rd quarter worth about $26,000. Jane Street Group LLC purchased a new position in shares of NeuroSense Therapeutics during the 2nd quarter valued at about $54,000. Yorkville Advisors Global LP purchased a new position in shares of NeuroSense Therapeutics during the 4th quarter valued at about $77,000. Finally, Squarepoint Ops LLC lifted its position in NeuroSense Therapeutics by 91.0% in the 3rd quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares during the last quarter. Institutional investors own 1.04% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Or Eisenberg acquired 250,000 shares of the company’s stock in a transaction dated Tuesday, June 16th. The stock was bought at an average cost of $0.80 per share, with a total value of $200,000.00. Following the acquisition, the chief financial officer owned 1,504,050 shares of the company’s stock, valued at approximately $1,203,240. The trade was a 19.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CEO Alon Ben-Noon bought 250,000 shares of the business’s stock in a transaction that occurred on Tuesday, June 16th. The stock was bought at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the transaction, the chief executive officer directly owned 4,534,233 shares of the company’s stock, valued at $3,627,386.40. This represents a 5.84% increase in their position. The SEC filing for this purchase provides additional information. Insiders own 27.40% of the company’s stock.

About NeuroSense Therapeutics

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.